VF
ZBIO

Virtu Financial’s ProShares UltraPro Short NASDAQ Biotechnology ZBIO Stock Holding History

Virtu Financial’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12,754
Closed -$169K – 2057
2019
Q1 		$169K Sell
12,754
-2,739
-18% -$39.8K 0.01% 1050
2018
Q4 		$339K Sell
15,493
-13,202
-46% -$243K 0.02% 664
2018
Q3 		$370K Sell
28,695
-11,453
-29% -$165K 0.02% 743
2018
Q2 		$725K Buy
40,148
+27,310
+213% +$550K 0.04% 586
2018
Q1 		$269K Sell
12,838
-561
-4% -$11K 0.01% 1138
2017
Q4 		$304K Sell
13,399
-18,289
-58% -$425K 0.02% 1261
2017
Q3 		$659K Buy
31,688
+590
+2% +$14.1K 0.03% 700
2017
Q2 		$835K Buy
31,098
+25,724
+479% +$833K 0.12% 162
2017
Q1 		$180K Sell
5,374
-6,349
-54% -$234K 0.02% 367
2016
Q4 		$563K Sell
11,723
-16
-0.1% -$754 0.06% 226
2016
Q3 		$496K Sell
11,739
-8,465
-42% -$391K 0.09% 200
2016
Q2 		$1.31M Buy
20,204
+4,498
+29% +$277K 0.17% 114
2016
Q1 		$1.14M Buy
+15,706
New +$1.16M 0.16% 142
2015
Q4 		– Sell
-16,532
Closed -$1.08M – 476
2015
Q3 		$1.08M Buy
16,532
+10,279
+164% +$467K 0.14% 147
2015
Q2 		$277K Buy
+6,253
New +$271K 0.02% 269

Other funds holding ZBIO

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Virtu Financial's ZBIO Position: Q2 2019 in Review

Virtu Financial sold out of ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) in Q2 2019, closing a stake of 12,754 shares — an estimated $169K sold.

Virtu Financial first reported a position in ZBIO in Q2 2015 and held it in 15 quarters. The position peaked at $1.31M in Q2 2016. 5 funds tracked by Wall St. Rank hold ZBIO as of Q2 2019.

  • Virtu Financial reported no remaining ProShares UltraPro Short NASDAQ Biotechnology position as of Q2 2019 after selling out during the quarter.
  • Virtu Financial sold 12,754 ProShares UltraPro Short NASDAQ Biotechnology shares in Q2 2019, an estimated $169K.
  • Virtu Financial first reported a position in ProShares UltraPro Short NASDAQ Biotechnology in Q2 2015 and held it in 15 quarters.
  • Virtu Financial's ProShares UltraPro Short NASDAQ Biotechnology position peaked at $1.31M in Q2 2016.
  • 5 funds tracked by Wall St. Rank held ProShares UltraPro Short NASDAQ Biotechnology as of Q2 2019.

Based on Virtu Financial's 13F filing for Q2 2019, filed 13 Aug 2019.